TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05443087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling to build population pharmacokinetics model
Description: Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received
Study: NCT06029933

Intervention type: BIOLOGICAL
Intervention: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
Description: Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.

Intervention type: BIOLOGICAL
Intervention: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Description: Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
Study: NCT05321706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg
Description: Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
Study: NCT06546553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07826390
Description: PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC (anti-PD-1 + platinum -based chemo)
Description: Standard of Care (anti-PD-1 + platinum -based chemo)
Study: NCT05580159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SW-BIC-213
Description: The patient will take a single 25 μg dose mRNA vaccine SW-BIC-213.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
Description: The patient will take a third dose of COVID-19 Inactivated vaccine.
Study: NCT01025934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Study: NCT04845035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: By mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: By mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berlin-Frankfurt-Münster Chemotherapy
Description: with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate and Cytarabine
Description: Intrathecal
Study: NCT05763992

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
Description: Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
Description: Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
Study: NCT04626973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)
Description: For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 10 or 20 mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin monotherapy (rosuvastatin or atorvastatin)
Description: For statin naive patients, patients would initially receive Rosuvastatin 20mg or Atorvastatin 40 or 80 mg.~For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<55 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Statin Combination therarpy (ezetimibe plus rosuvastatin)
Description: For statin naive patients, patients would initially receive Ezetimibe 10mg plus Rosuvastatin 5 or 10mg.~For non-statin naive patients, regimens are to be changed to the equivalent dose of ezetimibe+rosuvastatin combination in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin monotherapy (rosuvastatin or atorvastatin)
Description: For statin naive patients, patients would initially receive Rosuvastatin 10 or 20mg or Atorvastatin 20 or 40mg. For non-statin native patients, regimens are to be change to equivalent dose of atorvastatin or rosuvastatin in case of already achieved LDL-cholesterol target (\<70 mg/dL) and to be dosed up than the equivalent dose of study drugs in case of not yet achieved LDL-cholesterol target.
Study: NCT04575727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MPC6827
Description: Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MPC6827
Description: Subjects will receive a microdose ( 10 µg) of \[11C\]MPC6827 (dose of 20 mCi)
Study: NCT05951725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)
Description: Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP
Description: Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib
Description: Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTcP
Description: Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-Hib
Description: Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTcP
Description: Three doses of basic immunization were completed at 2, 4 and 6 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study: NCT05282849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided fascia iliaca block
Description: ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided quadratus lumborum block
Description: ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
Study: NCT06487819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of a rubber dam during dental treatments for varying durations.
Description: Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of a rubber dam during dental treatments for varying durations.
Description: Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of a rubber dam during dental treatments for varying durations.
Description: Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).
Study: NCT05518760

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05942079

Intervention type: OTHER
Intervention: REİKİ
Description: Reiki is applied as an alternative and complementary treatment method.
Study: NCT04572256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo will be taken daily for 6 months post surgery.
Study: NCT06004596

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 13C-Spirulina Gastric Emptying Breath Test (GEBT)
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-Spirulina Gastric Emptying Breath Test (GEBT)
Description: Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat
Description: Diagnostic test - repeat for biological variability deterination
Study: NCT04810039

Intervention type: OTHER
Intervention: Predict the outcome of the Glasgow Outcome Scale
Description: Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
Study: NCT05494229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pars-plana vitrectomy
Description: Pars-plana vitrectomy
Study: NCT05970380

Intervention type: OTHER
Intervention: Erector spinae plane block
Description: Local anesthetic solution (40 mL 0.25% bupivacaine totally) will be given bilaterally between the processus transversalis of the fractured vertebra and the erector spinae muscle under ultrasound imaging by an anesthesiologist.

Intervention type: OTHER
Intervention: Local anesthesia
Description: Local anesthetic solution (20 mL 0.25% bupivacaine) will be given extrapedicular part of the fractured vertebra by the surgeon.
Study: NCT06620380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharmacoscopy 1.0
Description: Pharmacoscopy is currently an academically developed platform. The study is designed to investigate the clinical performance of this academic platform. In the interventional arm, the best candidate agent defined by pharmascopy will be considered to guide the therapeutic decision for each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The next systemic treatment after surgery will be discussed, with the investigator and at the tumor board, considering also standard histopathological and molecular analysis, including next generation sequencing, molecular profiling analysis and previous treatments received
Study: NCT05251363

Intervention type: DEVICE
Group type: OTHER
Intervention: Solia S lead
Description: The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
Study: NCT06473597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: NURTEC ODT 75 mg orally disintegrating tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan Benzoate
Description: Rizatriptan ODT 10mg orally disintegrating tablets
Study: NCT05814094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
Study: NCT05756790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Breathalyzer
Description: Counseling plus mobile breathalyzer/ app
Study: NCT05554913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05306782

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Electrical Stimulation
Description: transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Electrical Stimulation
Description: transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Electrical Stimulation
Description: transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech Therapy
Description: Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
Study: NCT06580600

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Point of care respiratory virus testing
Description: Patients to be randomised to receive OCS based on the the result of the RSV results within their respiratory virus test. This test will be performed as a point of care (POC) test in ED.~This intervention will stratify the randomisation in a 1:1 ratio, to receive OCS or not.~NB) Whilst the respiratory pathogen test is not routine care to determine the OCS prescription, it is frequently used within this setting. Additionally both the receipt (or not the receipt) of OCS is within standard care pathway. For the purpose of the trial OCS = Dexamethasone, which is delivered as oral suspension 300mcg/kg as per standard practice within the local Trust.
Study: NCT06579183

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Strength VitaJoy (ES/VJ)
Description: Extra Strength VitaJoy Capsule, 2 capsules in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Strength Vita Calm (ES/VC)
Description: Extra Strength Vita Calm Capsule, 2 capsules in the evening

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, 4 capsules in the morning and evening respectively
Study: NCT04754438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: Electronically delivered cognitive behavioural therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Coaching
Description: Electronically delivered mental health coaching
Study: NCT06126835

Intervention type: DRUG
Intervention: Ozanimod
Description: Women with UC exposed to ozanimod during pregnancy

Intervention type: DRUG
Intervention: Conventional therapy
Description: Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy

Intervention type: DRUG
Intervention: Advanced therapy
Description: Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
Study: NCT06433661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive single dose of oral Etavopivat in each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive single dose of oral Etavopivat in each treatment period.